Chris Martin mortified after catching Astronomer CEO, HR chief on Coldplay kiss cam: ‘Hope we didn't do something bad'
A mortified Chris Martin struggled to carry on his concert Wednesday night after cameras at his Boston show caught Astronomer CEO Andy Byron allegedly cheating on his wife with his HR chief Kristin Cabot.
'I hope we didn't do something bad…' Martin said in a newly surfaced clip from the show that was shared on X.
The businessman and Cabot made headlines on Thursday morning after a video of them being caught on the concert's kiss cam went viral.
In the clip that's been circulating on social media, the pair were seen swaying with their hands wrapped around each other as Martin moved the 'kiss cam' around Gillette Stadium.
'Look at these two,' the 'Yellow' hitmaker, 48, said.
The pair appeared to be horrified by the camera catching them off guard as Cabot immediately turned around and Byron ducked out of view.
'Either they're having an affair or they're just very shy,' Martin added, which elicited a string of equal cheers and gasps from the audience.
Soon after the incident set the internet ablaze, Byron's wife, Megan Kerrigan Byron, deleted her social media page.
And shortly before taking down her profile, she deleted her surname from her account.
As we previously reported, Byron became the CEO for the New York-based business in July 2023, according to his since-deleted LinkedIn account.
Cabot later joined the company as its chief human resources officer in November 2024. However, a post announcing her role has since been wiped from her LinkedIn page.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Does this look like a real woman? AI Vogue model raises concerns about beauty standards
There's a new supermodel in town. She's striking, stylish... and not real. In August's print edition of Vogue, a Guess advert features a flawless blonde model showing off a striped maxi dress and a floral playsuit from the brand's summer collection. In small print in one corner, the ad reveals that she was created using AI. While Vogue says the AI model was not an editorial decision, it is the first time an AI-generated person has featured in the magazine. The advert has been met with controversy and raises questions about what this means for real models who have fought for greater diversity, and for consumers - particularly young people - already struggling with unrealistic beauty standards. Seraphinne Vallora is the company behind Guess's controversial advert. Its founders, Valentina Gonzalez and Andreea Petrescu, tell the BBC they were approached by Guess's co-founder, Paul Marciano, on Instagram and were asked to create an AI model as part of the brand's summer campaign. "We created 10 draft models for him and he selected one brunette woman and one blonde that we went ahead and developed further," Gonzalez says. She explains there's often a misconception that AI image generation is simple, saying it is actually a complex process. The company has five employees who create AI models, and it can take up to a month from idea inception to the completed product. The pair say they charge anywhere up to low six figures for a client like Guess. 'Disheartening' But Felicity Hayward, a plus-size model who has been in the industry for more than a decade, says using AI models in fashion campaigns "feels lazy and cheap". "Either Guess is doing this to create a talking point and get free publicity or they want to cut costs and don't think about the implications of that." She describes Vogue's decision to include the advert as "very disheartening and quite scary", and worries it could undermine years of work towards more diversity in the industry. The fashion world was making real progress to be more inclusive in the 2010s - the decade saw Valentina Sampaio become the first openly trans model to walk for Victoria's Secret, Halima Aden was the first hijab-wearing model in global campaigns, and brands like Savage x Fenty featured plus-size models on the runway. But in recent years, Hayward believes, the industry has slipped backwards because "these people are just not getting booked any more". And the use of AI models is "another kick in the teeth, and one that will disproportionately affect plus-size models", she warns. Gonzalez and Petrescu are adamant they don't reinforce narrow beauty standards. "We don't create unattainable looks - actually the AI model for Guess looks quite realistic," Petrescu says. "Ultimately, all adverts are created to look perfect and usually have supermodels in, so what we are doing is no different." The pair admit the AI images on their company's Instagram page are lacking in diversity and promote unrealistic beauty standards. They say they have tried to be more inclusive, but it's the users who don't engage much with those posts. "We've posted AI images of women with different skin tones, but people do not respond to them - we don't get any traction or likes," Gonzalez tells the BBC. "At the end of the day, we are a business and use images on Instagram that will create a conversation and bring us clients." The company is yet to experiment with creating plus-size women, claiming "the technology is not advanced enough for that". An ad campaign by Dove in 2024 was designed to highlight the biases in AI. In the advert, an image generator is asked to create the most beautiful woman in the world and produces virtually indistinguishable women who are young, thin and white, with blonde hair and blue eyes. The images generated look similar to the Guess AI model. Hayward worries that seeing these unattainable images could have an impact on people's mental health and negatively affect their body image. Concern around unrealistic beauty standards and the damaging effects they can have is nothing new. But unlike traditional airbrushing, which at least began with a real person, these AI models are digitally created to look perfect, free from human flaws, inconsistencies or uniqueness. While some high-profile figures such as Ashley Graham, Jameela Jamil and Bella Thorne have spoken out against image editing and refuse to have their pictures Photoshopped, the use of AI sidesteps such conversations entirely. Vogue's decision to include an AI-generated advert has caused a stir on social media, with one user on X writing: "Wow! As if the beauty expectations weren't unrealistic enough, here comes AI to make them impossible. Even models can't compete." Vanessa Longley, CEO of eating disorder charity Beat, tells the BBC the advert is "worrying". "If people are exposed to images of unrealistic bodies, it can affect their thoughts about their own body, and poor body image increases the risk of developing an eating disorder," she says. 'Exceptionally problematic' Adding to the issue is the lack of transparency - it is not a legal requirement to label AI-generated content in the UK. While Guess labelled its advert as AI-generated, the disclaimer is small and subtle. Readers may overlook it and, at a glance, the image appears entirely lifelike. Sinead Bovell, a former model and now tech entrepreneur, wrote an article for Vogue five years ago about the risks of AI replacing modelling. She tells the BBC that not labelling AI content clearly is "exceptionally problematic" because it could have a detrimental impact on people's mental health. "Beauty standards are already being influenced by AI. There are young girls getting plastic surgery to look like a face in a filter – and now we see people who are entirely artificial," she says. Aside from the impact AI models could have on a consumer, especially if unlabelled, what about the impact of this technology on those working in the fashion industry? Sara Ziff is a former model and founder of Model Alliance, an organisation that aims to advance workers' rights in the fashion industry. She says Guess's AI campaign is "less about innovation and more about desperation and need to cut costs". More broadly, the former model thinks AI in the fashion industry is not inherently exploitative, but can often come at the expense of the people who bring it to life because there are many more staff involved in a photoshoot than just the model and the photographer. "AI can positively impact the industry, but there need to be meaningful protections for workers," she explains. 'Supplement not replace' Seraphinne Vallora rejects the notion that it is putting people out of work, and says its pioneering technology "is supplementary and not meant to replace models". "We're offering companies another choice in how they market a product," Petrescu explains. The pair add that they have created jobs with their company, and part of the process of creating AI models requires them to hire a real model and photographer to see how the product looks on a person in real life. However, its website lists one of the benefits of working with them as being cost-efficient because it "eliminates the need for expensive set-ups, MUA artists, venue rentals, stage setting, photographers, travel expenses, hiring models". Vogue has come under fire for including the advert in its print edition, with one person on X saying the fashion magazine had "lost credibility". Bovell says the magazine is "seen as the supreme court of the fashion industry", so allowing the AI advert to run means they are "in some way ruling it as acceptable". The BBC approached Vogue and Guess for comment. Vogue said it was an advert, not an editorial decision, but declined to respond further. So, what does the future of the modelling industry look like? Gonzalez and Petrescu believe that as their technology improves, they will be even more in demand by brands looking to do things differently. Bovell thinks there will be more AI-generated models in the future, but "we aren't headed to a future where every model is created by AI". She sees positives in the development of AI in the industry - predicting that anybody could "start to see ourselves as the fashion models" because we will be able to create a personal AI avatar to see how clothes look and fit. However, she adds that we may get to the stage of "society opting out, and not being interested in AI models because it's so unattainable and we know it's not real". More Weekend Picks The procedures driving UK's cosmetic surgery rise Women share their bittersweet experience after taking weight-loss drugs Can LED face masks transform your skin? Here's what the experts say Solve the daily Crossword
Medscape
41 minutes ago
- Medscape
Ovarian Cancer Risk Rises Soon After IBS Diagnosis
TOPLINE: Women with a new diagnosis of irritable bowel syndrome (IBS) have a significantly higher risk for ovarian cancer at 3 months and 6 months post-diagnosis, but this risk is no longer elevated beyond 8 months. METHODOLOGY: Ovarian cancer often presents with nonspecific symptoms overlapping those of IBS. The frequency of misdiagnosis remains unknown, and not all IBS guidelines recommend screening for ovarian cancer. Researchers conducted a retrospective cohort study using US administrative claims data to compare ovarian cancer incidence in adult women with and without a new IBS diagnosis. Diagnostic codes were used to identify cases of IBS and ovarian cancer. TAKEAWAY: The cohort comprised 9804 women with IBS and 79,804 women without IBS, identified between January 2017 and December 2020. Women with IBS had a significantly higher risk for ovarian cancer at 3 months (hazard ratio [HR], 1.71; P = .02) and 6 months (HR, 1.43; P = .02), but not beyond 8 months post-diagnosis. Women with both IBS and endometriosis had an even greater risk for ovarian cancer at 3 months (HR, 4.20; P = .01), 6 months (HR, 3.52; P = .01), and after 1 year (HR, 2.67; P = .04). Increasing age was significantly associated with higher ovarian cancer incidence only in women younger than 50 years (HR, 1.07; P < .01), regardless of IBS status. IN PRACTICE: 'Identifying patient-specific risk factors, such as chronic pelvic pain or endometriosis, could help develop tailored risk profiles and improve the approach to personalized care in women with IBS-type symptoms,' the authors wrote. SOURCE: This study was led by Andrea Shin, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles. It was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: The use of diagnostic codes for identifying IBS may have led to misclassification or reflected symptoms rather than confirmed and validated diagnosis. DISCLOSURES: This study received support from the National Institutes of Health. Some authors reported serving as consultants, advisors, and/or receiving research support from pharmaceutical and healthcare companies; one author reported having stock options. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
41 minutes ago
- Medscape
Benzene in Acne Products: What to Know Now
When an independent laboratory filed a citizen's petition in March 2024, urging the FDA to recall and suspend the sale of acne products containing benzoyl peroxide after finding what it termed unacceptably high levels of benzene in acne products it tested, it ignited a range of reactions in the medical community and consumers. Responses ranged from fear to indifference, with even some dermatologists passing off the request as nonsense. However, concerns about the potential for benzoyl peroxide-containing acne products to break down into benzene, a known human carcinogen, have been ongoing. In recent months, as research has accumulated, so has a clearer picture of the risk. The FDA has taken action, although some contend the agency has not done enough, and experts involved are better focused — and sometimes in closer agreement — on how to move forward to increase safety for the products, considered one of the most effective topical acne treatments and the only effective remedy for many patients. Medscape Medical News reached out to John S. Barbieri, MD, MBA, assistant professor of dermatology at Harvard Medical School and director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital, both in Boston, and David Light, president and co-founder of Valisure, the independent laboratory in New Haven, Connecticut, that filed the petition, asking for an update of what they've found out in recent months (they both have published research recently), what they believe needs to be done moving forward, and their advice on how clinicians should be talking to their patients about the products. 'Right now, to me, it's a nonissue clinically,' said Barbieri, who has researched and written about the issue extensively. 'I don't worry about this in my day-to-day practice.' However, he's adamant that more needs to be done to maximize the safety of the products, that patients need to be educated about precautions they can take, and that manufacturers need to focus on getting the benzene levels in their products to what he and others say is achievable — zero. Product Heterogeneity Researchers have found a wide range of levels of benzene in products. That's good news, so to speak, in regard to fixing the problem. As Barbieri and Christopher Bunick, MD, PhD, associate professor of dermatology at Yale University School of Medicine, New Haven, Connecticut, wrote in a recent Viewpoint in JAMA Dermatology, 'there has been considerable heterogeneity observed between brands and product lines, suggesting opportunities to improve formulation, production, and distribution practices to maximize the safety of benzoyl peroxide-containing products.' The range of benzene found, for instance, in the Valisure analysis leading to the citizen's petition was sometimes over 800 times the FDA's conditional limit of 2 parts per million. The JAMA paper also cites a study, published in May 2025, by Bunick, Light, and others, finding that cold storage may reduce benzene formation, and a study co-authored by Barbieri, which found that leave-on benzoyl peroxide products contained lower concentrations of benzene, possibly because they are often manufactured in smaller batches than washes 'and thus may cool more quickly,' they wrote. Recent Recalls In March 2025, the FDA alerted the public and industry to the results of its testing of 95 acne products with benzoyl peroxide for possible benzene contamination, following the receipt of the Valisure test results. As a result of the FDA alert, six companies voluntarily recalled some of their products, and another company voluntarily recalled its product after its own testing. FDA Input? Under nonbinding FDA guidance issued in December 2023, benzene levels in products using carbomers (thickeners) should not exceed 2 parts per million. Medscape Medical News reached out to the FDA, asking if the agency had any other information pertaining to developments in the manufacturing of benzoyl peroxide acne products. A spokesperson referred only to the March 2025 information about recalls and its finding that more than 90% of the benzoyl peroxide acne products it tested had undetectable or very low levels of benzene. Manufacturers' Mission Manufacturers need to do more, Light and Barbieri agreed, to monitor benzene levels and reduce them. 'I'm quite supportive of the paper they wrote,' Light told Medscape Medical News , referring to the JAMA update co-authored by Barbieri and Bunick. 'I appreciate their push on the manufacturers' side,' a stance Light has taken from the start. Information on exactly what the product manufacturers are doing, even after the March recalls and the FDA testing, is scarce, Light and Barbieri agreed. (Light's analyses have previously been the target of some criticism, contending he is mostly interested in winning lawsuits against companies and boosting profits. He has filed patents related to, among other areas, the prevention of the formation of impurities, including benzene, in drug products such as benzoyl peroxide-containing products. In response, Light said his goals have always been focused on public health and consumer protection. 'Our analyses have not only been rigorously reviewed through the peer-review process in multiple journals,' he said, 'but each of our five FDA Citizen Petitions on benzene contamination in major consumer product categories has been followed by testing and validation by regulators and companies that confirmed unacceptably high levels of benzene and initiated recalls.') The Consumer Health Products Association, a trade group that many of the benzoyl peroxide product manufacturers belong to, posted the following statement on its site after the citizen's petition was filed last year: 'Benzene is not intentionally added to any consumer product, and it is important that proper quality control measures are in place to both detect impurities and reduce potential contamination during the manufacturing process.' But it offered no more specific information about individual manufacturers' procedures or attempts at improvements. Beyond quality control measures, manufacturers must pay attention to shipping and distribution, which can affect benzene levels as temperatures rise, Barbieri said. 'Consumer confidence is really important here,' he added. Manufacturers should also transparently share their benzene data, Barbieri and Light agreed. Besides acne products, according to the FDA, hand sanitizers, aerosol antiperspirants, and sunscreen sprays have been recalled because of benzene concerns. Empowering Patients Meanwhile, clinicians can advise patients to take a number of steps to minimize the risk for benzene exposure, according to Barbieri and Light. Discarding expired products or those that have been exposed to high temperatures — such as being left in a hot car — is one recommendation. Replacing products every 10-12 weeks is also probably wise, Barbieri said, but he concedes that more data is needed about the stability of the products at room temperature. Whether refrigerating the products is better than keeping them at room temperature hasn't been fully researched, he noted. Lowering the temperature does help with benzene formation, Light said. In his studies, he found that a single acne product incubated at 158 °C, similar to a hot car, released benzene at concentrations about 1270 times higher than the US Environmental Protection Agency threshold for cancer risk via long-term inhalation. He also cautions against storing the products in the bathroom medicine cabinet because of the higher temperatures. In addition, consumers shouldn't rely on 'best products' lists based on analyses of benzene levels, Barbieri told Medscape Medical News , because the same product could have been purchased in different ways — such as picking it up from the store directly or ordering it online and then having it sit on a hot doorstep for hours. Be cautious using online retailers and pharmacies, he said, for those reasons — the products could have had potentially higher temperature exposure during shipping. Ultraviolet exposure is similar to heat in its effects, Light pointed out. Barbieri said those who use leave-on products should consider sun protection, which, he added, is a useful general recommendation for acne management in general. Looking Forward: Getting to Zero While progress has been made, and awareness of the risks has increased, there's work to be done, experts agreed. 'It's still an important and relevant issue,' Barbieri said. 'We want to be doing as much as we can to mitigate the risk as much as possible. Even if the risk is 0.00001, if we can make it zero, we should make it zero.' Barbieri and Bunick have reported no relevant disclosures. Light has filed patents related to the prevention of the formation of impurities, including benzene, in drug products, such as benzoyl peroxide products. The Journal of Investigative Dermatology study published in May 2025 was funded by Valisure.
